Back to Search Start Over

Multifactorial chylomicronemia syndrome.

Authors :
Chait A
Source :
Current opinion in endocrinology, diabetes, and obesity [Curr Opin Endocrinol Diabetes Obes] 2024 Apr 01; Vol. 31 (2), pp. 78-83. Date of Electronic Publication: 2023 Nov 23.
Publication Year :
2024

Abstract

Purpose of Review: The aim of this review was to understand the role of multifactorial chylomicronemia syndrome (MFCS) as a cause of severe hypertriglyceridemia; to distinguish it from other causes of severe hypertriglyceridemia; and to provide a rational approach to treatment.<br />Recent Findings: There have been advances in understanding the genetic underpinning of MFCS, and a better appreciation as to how to differentiate it from the much rarer familial chylomicronemia syndrome, in which there are substantial differences in the approach to their treatment. New approaches to triglyceride lowering will help reduce the risk of pancreatitis, the major complication of MFCS.<br />Summary: MCSF is a condition in which plasma triglyceride levels are severely elevated, usually to due exacerbation of common genetic forms of hypertriglyceridemia by secondary causes of hypertriglyceridemia and/or triglyceride-raising drugs. Triglyceride-induced pancreatitis can be prevented by markedly reducing triglyceride levels by treating secondary causes and/or eliminating of triglyceride-raising drugs, and by using triglyceride-lowering drugs, especially fibrates. MFCS also increases cardiovascular disease risk, for which lifestyle measures and drugs are required.<br /> (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1752-2978
Volume :
31
Issue :
2
Database :
MEDLINE
Journal :
Current opinion in endocrinology, diabetes, and obesity
Publication Type :
Academic Journal
Accession number :
37994661
Full Text :
https://doi.org/10.1097/MED.0000000000000846